SNMMI: Study Finds FAP-Targeted Radioligand Therapy Beneficial for Patients with Advanced Sarcomas
Diagnostic Imaging
JUNE 8, 2024
The use of 90Y-FAPI-46 radioligand therapy resulted in controlled disease progression in nearly half of a 30-person cohort largely comprised of patients with advanced sarcomas, according to new research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Let's personalize your content